Citius Oncology adds Jonathan Peri to board, expanding to nine members

Citius Oncology, Inc. (Nasdaq: CTOR), described in the filing as an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc.¹, announced on August 12, 2026 that its Board of Directors appointed Jonathan Peri, Ph.D., J.D., as an additional independent director effective August 10, 2026. The appointment followed a company statement that a unanimous vote of approval by the Board expanded the Company's Board of Directors to nine members.¹

According to the filing, on August 7, 2026 the Board formally acted to expand to nine directors and named Peri as a Class I member of the Board, effective August 10, 2026, to serve until the Company's 2028 annual meeting of stockholders or until his successor is duly elected and qualified.¹ The company said the Board has determined that Dr. Peri is an independent director under the relevant SEC and Nasdaq Stock Market listing rules,¹ and noted that following Dr. Peri's appointment, the Board remains majority independent.¹

Peri's background includes serving as President of Manor College since October 2015¹ and previously as Vice President and General Counsel for Neumann University from July 2006 to October 2015.¹ He also served on the advisory board of First State Bank, the oldest bank in Texas, from March 2021 to March 2024, and was lead advisory director beginning in 2023.¹ He holds degrees including a B.A in Theology from Villanova University, a J.D. from Widener University, a doctorate in Organizational Leadership from Eastern University and an MLE Certificate from Harvard University.¹

The filing stated that there have been no transactions in which the Company has participated and in which Dr. Peri had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.¹ The company also noted that in December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy.¹